Karolinska Development

Declaration of Voting Results & Voting Rights Announcements • Feb 28, 2022

Change of number of shares and votes in Karolinska Development

STOCKHOLM, SWEDEN – February 28, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that the number of shares and votes has changed during February 2022 as a result of the rights issue resolved by the Board of Directors on December 10, 2021 and approved at the Extraordinary General Meeting on January 12, 2022.

Today, the last trading day of the month, there are 270,077,594 shares, representing a total of 293,074,943 votes outstanding in the company, distributed among 2,555,261 shares of series A (with 25,552,610 votes) and 267,522,333 shares of series B (with 267,522,333 votes).

For further information, please contact:

Viktor Drvota, CEO, Karolinska Development AB Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com

Johan Dighed, General Counsel and Deputy CEO, Karolinska Development AB Phone: +46 70 207 48 26, e-mail: johan.dighed@karolinskadevelopment.com

TO THE EDITORS

About Karolinska Development AB

Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and cofunded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has a portfolio of nine companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.

For more information, please visit www.karolinskadevelopment.com

This information is information that Karolinska Development AB (publ) (Nasdaq Stockholm: KDEV) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of Viktor Drvota, at 08:00 CET on February 28, 2022.